Liang Zhang

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $380 million acquisition of HemaCare Corporation. The proposed purchase price equates to $25.40…

Davis Polk advised the initial purchasers in connection with a Rule 144A/Regulation S offering by AES Gener S.A. of an aggregate principal amount of $450 million of 6.350% junior…

Davis Polk advised the underwriters in connection with an SEC-registered offering by AbbVie Inc. of €1.4 billion aggregate principal amount of senior notes in two series, consisting of €750…

Davis Polk advised the joint book-running managers in connection with an offering by Beazer Homes USA, Inc. of $350 million aggregate principal amount of its 7.250% notes due 2029. Davis…

Davis Polk advised the joint book-running managers in connection with the SEC-registered offering by Deciphera Pharmaceuticals, Inc. of 10,810,810 shares of common stock for gross proceeds…

Davis Polk advised the underwriters in connection with an SEC-registered offering of $1 billion aggregate principal amount of 2.950% notes due 2029 and $400 million aggregate principal…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A/Regulation S offering by Gran Tierra Energy Inc. of $300 million aggregate principal amount…

Davis Polk advised the joint book-running managers in connection with a Rule 144A/Regulation S notes offering by Penske Truck Leasing Co., L.P. and PTL Finance Corporation of $700…

Davis Polk advised the initial purchasers in connection with the offering by National Life Insurance Company of an additional $127.943 million of its existing 5.250% fixed-to-floating-rate…

Davis Polk advised Toyota Motor Credit Corporation in connection with an SEC-registered offering of $1.25 billion aggregate principal amount of floating-rate medium-term notes, Series B due…